Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease

Circulation. 2017 May 30;135(22):2204-2206. doi: 10.1161/CIRCULATIONAHA.117.027705. Epub 2017 Apr 26.

Authors

Joshua W Knowles¹, William B Howard², Lala Karayan², Seth J Baum², Katherine A Wilemon², Christie M Ballantyne², Kelly D Myers²

Affiliations

¹ From Stanford University, CA (J.W.K.); The FH Foundation, Pasadena, CA (J.W.K., L.K., K.A.W.); Atomo, Inc., Austin, TX (W.B.H., K.D.M.); Preventive Cardiology Inc., Boca Raton, FL (S.J.B.); and Baylor College of Medicine, Houston, TX (C.M.B.). [email protected].
² From Stanford University, CA (J.W.K.); The FH Foundation, Pasadena, CA (J.W.K., L.K., K.A.W.); Atomo, Inc., Austin, TX (W.B.H., K.D.M.); Preventive Cardiology Inc., Boca Raton, FL (S.J.B.); and Baylor College of Medicine, Houston, TX (C.M.B.).

PMID: 28446516
DOI: 10.1161/CIRCULATIONAHA.117.027705

No abstract available

Keywords: PCSK9 inhibitor, human; atherosclerosis; familial hypercholesterolemia.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anticholesteremic Agents / administration & dosage*
Anticholesteremic Agents / adverse effects
Atherosclerosis / blood
Atherosclerosis / drug therapy*
Atherosclerosis / physiopathology
Cholesterol, LDL / blood
Databases, Factual*
Ezetimibe / administration & dosage*
Ezetimibe / adverse effects
Female
Humans
Hypercholesterolemia / blood
Hypercholesterolemia / drug therapy*
Hypercholesterolemia / physiopathology
Male
PCSK9 Inhibitors*

Substances

Anticholesteremic Agents
Cholesterol, LDL
PCSK9 Inhibitors
PCSK9 protein, human
Ezetimibe